Cargando…

Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling

BACKGROUND: To define protein molecular characteristics of tumor cells prior to, and immediately following, preoperative human epidermal growth factor receptor 2 (HER2)-targeted therapy that correlate with pathologic complete response (pCR) or non response (no pCR) to preoperative HER2-directed ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holmes, Frankie Ann, Espina, Virginia, Liotta, Lance A, Nagarwala, Yasir M, Danso, Michael, McIntyre, Kristi J, Osborne, Cynthia R C, Anderson, Thomas, Krekow, Lea, Blum, Joanne L, Pippen, John, Florance, Allison, Mahoney, Janine, O’Shaughnessy, Joyce A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915616/ https://www.ncbi.nlm.nih.gov/pubmed/24304724 http://dx.doi.org/10.1186/1756-0500-6-507

Ejemplares similares

Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer
por: Holmes, Frankie Ann, et al.
Publicado: (2018)

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
por: O’Shea, John, et al.
Publicado: (2017)

Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial
por: O’Shaughnessy, Joyce, et al.
Publicado: (2021)

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients
por: Paul, Devchand, et al.
Publicado: (2019)

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
por: Yardley, Denise A., et al.
Publicado: (2012)

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
por: Eustace, Alex J, et al.
Publicado: (2018)

Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies
por: O’Shaughnessy, Joyce, et al.
Publicado: (2015)

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
por: McIntyre, Kristi, et al.
Publicado: (2014)

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
por: McIntyre, Kristi, et al.
Publicado: (2014)

Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy
por: O’Shaughnessy, Joyce
Publicado: (2020)

Protein painting reveals solvent-excluded drug targets hidden within native protein–protein interfaces
por: Luchini, Alessandra, et al.
Publicado: (2014)

Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine
por: Levin, Maren K, et al.
Publicado: (2015)

The truth about economizing for college: shrinking the college tab
por: O'Shaughnessy, Lynn, et al.
Publicado: (2011)

PLZF Mediates the PTEN/AKT/FOXO3a Signaling in Suppression of Prostate Tumorigenesis
por: Cao, JingPing, et al.
Publicado: (2013)

Reverse-Phase Microarray Analysis Reveals Novel Targets in Lymph Nodes of Bacillus anthracis Spore-Challenged Mice
por: Popova, Taissia G., et al.
Publicado: (2015)

A conserved PTEN/FOXO pathway regulates neuronal morphology during C. elegans development
por: Christensen, Ryan, et al.
Publicado: (2011)

Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells
por: Popova, Taissia, et al.
Publicado: (2009)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

Chemokine-Releasing Microparticles Improve Bacterial Clearance and Survival of Anthrax Spore-Challenged Mice
por: Popova, Taissia G., et al.
Publicado: (2016)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Evaluation of an (131)I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers
por: Feng, Yutian, et al.
Publicado: (2022)

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
por: Turner, Nicholas, et al.
Publicado: (2021)

Whole Proteome Analysis of Mouse Lymph Nodes in Cutaneous Anthrax
por: Popova, Taissia G., et al.
Publicado: (2014)

Students Who Demonstrate Strong Talent and Interest in STEM Are Initially Attracted to STEM through Extracurricular Experiences
por: VanMeter-Adams, Amy, et al.
Publicado: (2014)

Immune-modulating Activity of Hydrogel Microparticles Contributes to the Host Defense in a Murine Model of Cutaneous Anthrax
por: Teunis, Allison L., et al.
Publicado: (2017)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Move to strike
por: O'Shaughnessy, Perri
Publicado: (2000)

Obstruction of justice
por: O'Shaughnessy, Perri
Publicado: (1997)

Marketing competitivo : un enfoque estratégico /
por: O'Shaughnessy, John
Publicado: (1991)

¿Por qué compra la gente?
por: O'shaughnessy, Jhon
Publicado: (1989)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2007)

Business Organization (RLE: Organizations)
por: O'Shaughnessy, John
Publicado: (2013)

Breach of promise /
por: O'Shaughnessy, Perri
Publicado: (1999)

The college solution: a guide for everyone looking for the right school at the right price
por: O'Shaughnessy, Lynn
Publicado: (2008)

The truth about maximizing college 529 accounts
por: O'Shaughnessy, Lynn
Publicado: (2011)

The truth about finding great academic fits in your college search
por: O'Shaughnessy, Lynn
Publicado: (2011)

The college solution: a guide for everyone looking for the right school at the right price
por: O'Shaughnessy, Lynn
Publicado: (2012)

Speech communications: human and machine
por: O'Shaughnessy, Douglas
Publicado: (2000)

Unlucky in law
por: O'Shaughnessy, Perri
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_4tf4s309lrfnn4e2pbj5s883g4